Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Full description
Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study.These information will be used to recommend target therapy which may be more likely to result in a beneficial response.Patients will receive target anti-tumor agents according to the result of genomic and proteomic profiling.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Have received following treatment before this study:
Have central nervous system metastasis;
History of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years;
Have symptomatic ascites and need for treatment;
Have serious concurrent illness including, but not limited to
be allergic or have contraindications to target medicines involved in this study, gemcitabine or oxaliplatin.
Primary purpose
Allocation
Interventional model
Masking
152 participants in 2 patient groups
Loading...
Central trial contact
liu yingbin, PHD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal